Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...

As Catalent sets up shop in a new headquarters and refines its corporate image under the ownership of Novo Holdings, the CDMO ...

Children’s Hospital Los Angeles (CHLA) is expanding its safety protocol for patients receiving Elevidys®, the FDA-approved ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Mizuho upgraded Sarepta Therapeutics Inc to Outperform from Neutral and raised its price target to $26 from $19, citing stronger-than-expected sales of its gene therapy Elevidys and growing confidence ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Sarepta Therapeutics (SRPT) surged after Mizuho upgraded to Outperform, citing strong Elevidys uptake and gene therapy ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.